ECRON ACUNOVA
 
 
 
 

"What makes a country competitive for clinical research?" an article by D. A. Prasanna in Biospectrum

 
Among the Asian nations, countries like India, China, and Korea are actively involved in global clinical trials only in the last few years. In spite of delayed entry, India and China are expected to have tremendous growth potential in clinical research due to their huge disease prevalence and treatment-naïve patient pools. India has the added benefits of vast genetically diverse population, well-equipped hospitals, and highly qualified English-speaking investigators making it one of the preferred destinations for conducting global clinical trials. The contract research and manufacturing services in India was expected to increase from $3.8 billion in 2010 to nearly $7.6 billion in 2012.

There is a 40-60% reduction in cost per person per trial when the research is conducted in India as opposed to in a developed country such as the United States. Due to the economy in India, compensation for participation can be relatively low while still acting as a sufficient motivation to participate. Often, clinical researchers are able to evade offering compensation entirely. In addition, many Indians have never been exposed to medications ensuring that no previous treatments could potentially interfere with the test.

Performing clinical trials in India is also beneficial for clinical researchers because of the Indian health care system and burden of diseases. This generates a desperate need for treatment among patients causing more to participate in trials. Also, researchers are in a challenging need to provide health care to participants. Clinical researchers are taking measures to increase the convenience and decrease the cost of clinical trials, aiming to bring better medicines closer to the patients.
 
 
Read this whitepaper in PDF format
 
Cancel
 
Whitepapers
 
Cancel
 
  Disclaimer | Privacy Policy | Site Map